Graves Disease Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-16　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2.30 Bn
2033 年預估規模: USD 3.26 Bn
年複合成長率 CAGR: 5.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-16頁數 168報告編號 CMI9337

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Graves Disease Market, By Disease Type (Overt Graves Disease and Subclinical Graves Disease), By Symptom (Thyrotoxicosis, Graves Orbitopathy (Ocular), Dermopathy (Pretibial Myxedema), and Other Systemic Manifestations), By Diagnostic Method (Clinical Evaluation, Imaging (Ultrasound, Radioiodine Uptake Scan, MRI/CT (for orbitopathy)), and Laboratory (TSH, Free T3/Free T4, TSH Receptor Antibodies (TRAb))), By Treatment Modality (Pharmacological (Antithyroid Drugs (Methimazole, Propylthiouracil, and Carbimazole), BetaBlockers, Corticosteroids, Immunosuppressants), Radioactive Iodine Therapy, Surgical (Total Thyroidectomy and Subtotal Thyroidectomy), Adjunctive/Ocular(Orbital Decompression, Rituximab, and Teprotumumab), and Supportive/Other (Lifestyle/Adjunctive Care)), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Home Care Settings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

According to Coherent Market Insights, the global graves’ disease market is estimated to be valued at USD 2.30 Bn in 2026 and is expected to reach USD 3.26 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033. Graves’ disease represents a critical segment within the global autoimmune disorders market, characterized by hyperthyroidism caused by thyroid-stimulating immunoglobulin (TSI) antibodies that overstimulate the thyroid gland. This autoimmune condition affects approximately 1-2% of the global population, with women being five to ten times more likely to develop the disease than men, typically manifesting between ages 30-50. The global graves’ disease market encompasses various therapeutic interventions including antithyroid medications (methimazole, propylthiouracil), radioactive iodine therapy, beta-blockers for symptom management, and surgical thyroidectomy procedures. The market is driven by increasing prevalence rates, enhanced diagnostic capabilities through advanced thyroid function tests and imaging technologies, and growing awareness about autoimmune thyroid disorders. Healthcare systems worldwide are witnessing rising demand for effective treatment modalities due to the chronic nature of the condition and its significant impact on patients' quality of life, including symptoms such as rapid heartbeat, weight loss, anxiety, and ophthalmopathy. The market landscape includes pharmaceutical companies developing novel therapeutic approaches, diagnostic equipment manufacturers, and healthcare service providers offering comprehensive treatment protocols, positioning graves’ disease as a substantial market opportunity within the broader endocrinology and immunology therapeutic areas. Market Dynamics The global graves’ disease market is propelled by several key drivers that collectively enhance market expansion and therapeutic advancement. The primary driver includes the rising global prevalence of autoimmune disorders, with environmental factors, genetic predisposition, and lifestyle changes contributing to increased incidence rates of graves’ disease across diverse demographics. Enhanced diagnostic capabilities through sophisticated thyroid function testing, including TSI antibody detection, thyroid ultrasound, and radioactive iodine uptake scans, facilitate early disease identification and appropriate treatment initiation, thereby expanding the patient pool seeking therapeutic interventions. Growing healthcare expenditure, improved insurance coverage for chronic autoimmune conditions, and increased patient awareness through digital health platforms and patient advocacy groups significantly boost market demand. However, the market faces notable restraints including high treatment costs associated with long-term medication regimens, potential side effects of antithyroid drugs leading to treatment discontinuation, and limited availability of specialized endocrinologists in emerging markets. Regulatory complexities surrounding radioactive iodine therapy, varying treatment guidelines across different regions, and challenges in achieving optimal treatment outcomes due to individual patient variability create additional market barriers. Despite these constraints, substantial opportunities emerge through the development of novel therapeutic modalities including monoclonal antibodies, immunomodulatory agents, and personalized medicine approaches based on genetic profiling. The integration of telemedicine platforms for remote patient monitoring, artificial intelligence-driven diagnostic tools, and patient-centric care models present significant growth opportunities. Additionally, expanding healthcare infrastructure in emerging economies, increasing research investments in autoimmune disease therapeutics, and growing focus on combination therapy approaches offer promising avenues for market participants to capitalize on unmet medical needs and enhance treatment outcomes for graves’ disease patients globally. Key Features of the Study • This report provides in-depth analysis of the global graves’ disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global graves’ disease market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Eli Lilly and Company, Merck & Co. Inc, GlaxoSmithKline plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Sanofi, Bayer AG, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, AbbVie Inc, Roche Holding AG, and Johnson & Johnson • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global graves’ disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global graves’ disease market Market Segmentation • Disease Type Insights (Revenue, USD Bn, 2021 - 2033) o Overt Graves’ Disease o Subclinical Graves’ Disease • Symptom Insights (Revenue, USD Bn, 2021 - 2033) o Thyrotoxicosis o Graves Orbitopathy (Ocular) o Dermopathy (Pretibial Myxedema) o Other Systemic Manifestations • Diagnostic Method Insights (Revenue, USD Bn, 2021 - 2033) o Clinical Evaluation o Imaging  Ultrasound  Radioiodine Uptake Scan  MRI/CT (for orbitopathy) o Laboratory  TSH  Free T3/Free T4  TSH Receptor Antibodies (TRAb) • Treatment Modality Insights (Revenue, USD Bn, 2021 - 2033) o Pharmacological  Antithyroid Drugs o Methimazole o Propylthiouracil o Carbimazole  Beta Blockers  Corticosteroids  Immunosuppressants o Radioactive Iodine Therapy o Surgical  Total Thyroidectomy  Subtotal Thyroidectomy o Adjunctive/Ocular  Orbital Decompression  Rituximab  Teprotumumab o Supportive/Other  Lifestyle/Adjunctive Care • End User Insights (Revenue, USD Bn, 2021 - 2033) o Hospitals o Specialty Clinics o Diagnostic Centers o Ambulatory Surgical Centers o Home Care Settings • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Pfizer Inc o Novartis AG o Eli Lilly and Company o Merck & Co. Inc o GlaxoSmithKline plc o Bristol Myers Squibb Company o Takeda Pharmaceutical Company Limited o AstraZeneca plc o Sanofi o Bayer AG o Teva Pharmaceutical Industries Ltd o Boehringer Ingelheim International GmbH o AbbVie Inc o Roche Holding AG o Johnson & Johnson

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Graves’ Disease Market, By Disease Type  Global Graves’ Disease Market, By Symptom  Global Graves’ Disease Market, By Diagnostic Method  Global Graves’ Disease Market, By Treatment Modality  Global Graves’ Disease Market, By End User  Global Graves’ Disease Market, By Distribution Channel  Global Graves’ Disease Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global Graves’ Disease Market, By Disease Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Overt Graves’ Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Subclinical Graves’ Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Graves’ Disease Market, By Symptom, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Thyrotoxicosis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Graves Orbitopathy (Ocular)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Dermopathy (Pretibial Myxedema)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Other Systemic Manifestations  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Graves’ Disease Market, By Diagnostic Method, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Clinical Evaluation  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Imaging o Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Ultrasound o Radioiodine Uptake Scan o MRI/CT (for orbitopathy) o Laboratory  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o TSH o Free T3/Free T4 o TSH Receptor Antibodies (TRAb) 7. Global Graves’ Disease Market, By Treatment Modality, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Pharmacological  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Antithyroid Drugs  Methimazole  Propylthiouracil  Carbimazole o Beta Blockers o Corticosteroids o Immunosuppressants o Radioactive Iodine Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Surgical  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Total Thyroidectomy o Subtotal Thyroidectomy o Adjunctive/Ocular  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Orbital Decompression o Rituximab o Teprotumumab o Supportive/Other  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Lifestyle/Adjunctive Care 8. Global Graves’ Disease Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Specialty Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Diagnostic Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Ambulatory Surgical Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Home Care Settings  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 9. Global Graves’ Disease Market, By Distribution Channel, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 10. Global Graves’ Disease Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 11. Competitive Landscape o Pfizer Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co. Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GlaxoSmithKline plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bristol Myers Squibb Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Takeda Pharmaceutical Company Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sanofi  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bayer AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmaceutical Industries Ltd  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Boehringer Ingelheim International GmbH  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AbbVie Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Roche Holding AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 12. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 13. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on 'Graves’ Disease Market' - Global forecast to 2033

提及公司

Pfizer IncNovartis AGEli Lilly and CompanyMerck & Co. IncGlaxoSmithKline plcBristol Myers Squibb CompanyTakeda Pharmaceutical Company LimitedAstraZeneca plcSanofiBayer AGTeva Pharmaceutical Industries LtdBoehringer Ingelheim International GmbHAbbVie IncRoche Holding AGJohnson & Johnson

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們